ScoreWhy is Sudeep Pharma Ltd ?
1
High Management Efficiency with a high ROE of 0%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.68 times
3
Poor long term growth as Operating profit has grown by an annual rate 0% of over the last 5 years
4
Flat results in Jun 26
- INTEREST(Latest six months) At Rs 4.50 cr has Grown at 30.43%
- PAT(Q) At Rs 40.55 cr has Fallen at -6.2% (vs previous 4Q average)
5
With ROE of 19.6, it has a Very Expensive valuation with a 12.5 Price to Book Value
- Over the past year, while the stock has generated a return of NA, its profits have risen by 25%
6
Falling Participation by Institutional Investors
- Institutional investors have decreased their stake by -2.21% over the previous quarter and collectively hold 17.46% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sudeep Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
33.98
Debt to EBITDA (avg)
0.72
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.65
Tax Ratio
23.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.46%
ROCE (avg)
24.88%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
60
Industry P/E
37
Price to Book Value
12.45
EV to EBIT
53.28
EV to EBITDA
49.72
EV to Capital Employed
12.01
EV to Sales
17.18
PEG Ratio
NA
Dividend Yield
0.15%
ROCE (Latest)
22.53%
ROE (Latest)
19.57%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Bullish
KST
Dow Theory
No Trend
Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
PAT(9M)
At Rs 136.89 cr has Grown at 31.99%
NET SALES(Latest six months)
At Rs 340.61 cr has Grown at 20.58%
-3What is not working for the Company
INTEREST(Latest six months)
At Rs 4.50 cr has Grown at 30.43%
PAT(Q)
At Rs 40.55 cr has Fallen at -6.2% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Sudeep Pharma
Net Sales - Latest six months
At Rs 340.61 cr has Grown at 20.58%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Sudeep Pharma
Interest - Latest six months
At Rs 4.50 cr has Grown at 30.43%
over previous Half yearly periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Profit After Tax (PAT) - Quarterly
At Rs 40.55 cr has Fallen at -6.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 43.23 CrMOJO Watch
Near term PAT trend is negative
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
